<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01776541</url>
  </required_header>
  <id_info>
    <org_study_id>V89_04</org_study_id>
    <nct_id>NCT01776541</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Healthy Adults</brief_title>
  <official_title>A Phase II, Randomized, Observer-Blind,Multi-Center, Study to Evaluate Safety, Tolerability and Immunogenicity of an Adjuvanted Cell Culture-Derived H5N1 Subunit Influenza Virus Vaccine at Two Different Formulations in Healthy Adult Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Vaccines</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Department of Health and Human Services</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate Safety, Tolerability and Immune Response of Adjuvanted H5N1 Cell Culture Derived
      Influenza Vaccine in Adult Subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentages Of Subjects Achieving Hemagglutinin Inhibition (HI) Titers ≥40 Against A/H5N1 Strain.</measure>
    <time_frame>Three weeks after 2nd vaccination (day 43)</time_frame>
    <description>The optimal aH5N1c vaccine formulation was evaluated in terms of percentages of subjects achieving HI titers ≥40 against homologous A/H5N1 strain, three weeks after second vaccination with either low dose or high dose of aH5N1c vaccine, according to the Center for Biologics Evaluation and Research (CBER) criterion.
CBER criterion for the adult population is met if the lower limit of the two-sided 95% confidence interval (CI) for the percentages of subjects achieving HI titer ≥40 meets or exceeds 70%.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentages Of Subjects Achieving Seroconversion Against A/H5N1 Strain.</measure>
    <time_frame>Three weeks after 2nd vaccination (day 43)</time_frame>
    <description>Immunogenicity was measured in terms of the percentages of subjects achieving seroconversion or significant increase in HI titer against the vaccine strain, three weeks after receiving two injections of low dose or high dose of aH5N1c vaccine according to the CBER criterion.
Seroconversion is defined as either a) in subjects with a prevaccination HI titer &lt;10, a postvaccination titer ≥40; or b) in subjects with prevaccination HI titer ≥10, a minimum four-fold rise in postvaccination HI antibody titer.
CBER criterion for the adult population is met if the lower limit of the two-sided 95% CI for the percentages of subjects achieving seroconversion for HI antibody titer meets or exceeds 40%.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AE), After Any Vaccination.</measure>
    <time_frame>From day 1 through day 7 after any vaccination.</time_frame>
    <description>Safety was assessed using the number of subjects who reported solicited local and systemic AEs following vaccination with either low or high dose of aH5N1c vaccine.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Reporting Unsolicited AEs After Any Vaccination.</measure>
    <time_frame>Any unsolicited AEs - day 1 through day 22 after any vaccination. SAEs, NOCDs. medically attended AEs, AESIs, AEs leading to study withdrawal- day 1 to day 387</time_frame>
    <description>Safety was assessed using the number of subjects who reported any unsolicited adverse events, adverse events possibly or probably related to study vaccine, serious adverse events (SAEs), new onset of chronic diseases (NOCDs), medically attended AEs, AEs of special interest (AESIs), AEs leading to withdrawal from study following vaccination with either low or high dose of aH5N1c vaccine.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Ratios Against A/H5N1 Strain Following 2-dose Vaccination Schedule of Either Low Dose or High Dose aH5N1c Vaccine.</measure>
    <time_frame>Day 1; day 22; day 43 and day 387</time_frame>
    <description>Immunogenicity was measured as the geometric mean ratio (GMR). The ratio of postvaccination to prevaccination HI GMTs, 3 weeks after first vaccination, 3 weeks after second vaccination and 12 months after second vaccination of either low dose or high dose of aH5N1c is reported.
The criterion is met according to the European Committee for Medicinal Products for Human Use (CHMP) criterion if the geometric mean increase GMR (day 43/day 1) in HI antibody titer is &gt;2.5 for subjects 18-60 years of age.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages Of Subjects With HI Titers ≥40 Against A/H5N1 Strain.</measure>
    <time_frame>Day 1, day 22, day 43 and day 387</time_frame>
    <description>Immunogenicity was assessed in terms of percentage of subjects achieving HI titers ≥40, 3 weeks after first vaccination, 3 weeks after second vaccination and 12 months after second vaccination of either low dose or high dose of aH5N1c according to the CHMP criterion.
European Licensure (CHMP) criterion is met if the percentage of subjects achieving (at day 43) HI titers ≥40 is &gt;70%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages Of Subjects Achieving Seroconversion Against A/H5N1 Strain.</measure>
    <time_frame>Day 22, day 43 and day 387</time_frame>
    <description>Immunogenicity was assessed in terms of percentages of subjects achieving seroconversion in HI titers, 3 weeks after first vaccination, 3 weeks after second vaccination and 12 months after second vaccination of either low dose or high dose aH5N1c vaccine according to the CHMP criterion.
Seroconversion is defined as: a) for subjects with a prevaccination HI titer &lt;10, a postvaccination titer ≥40; or b) for subjects with prevaccination HI titer ≥10, a minimum four-fold rise in postvaccination HI antibody titer.
The criterion is met according to the European (CHMP) guideline if the percentage of subjects achieving seroconversion (at day 43) is &gt;40%.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">979</enrollment>
  <condition>Pandemic H5N1 Influenza</condition>
  <arm_group>
    <arm_group_label>aH5N1c-High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received 2 injections of a high dose of cell culture-derived adjuvanted monovalent inactivated subunit H5N1 vaccine three weeks apart.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>aH5N1c-Low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received 2 injections of a low dose of cell culture-derived adjuvanted monovalent inactivated subunit H5N1 vaccine three weeks apart.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Adjuvanted H5N1 pandemic influenza vaccine</intervention_name>
    <description>Comparison of two doses of aH5N1c vaccine</description>
    <arm_group_label>aH5N1c-High Dose</arm_group_label>
    <arm_group_label>aH5N1c-Low dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy adult subjects 18 to 64 years of age,

          2. Individuals willing to provide written informed consent,

          3. Individuals in good health,

          4. Individuals willing to allow for their serum samples to be stored beyond the study
             period.

        Exclusion Criteria:

          1. Individuals not able to understand and follow study procedures,

          2. History of any significant illness,

          3. History of any chronic medical condition or progressive disease,

          4. Presence of medically significant cancer,

          5. Known or suspected impairment/alteration of immune function,

          6. Presence of any progressive or severe neurologic disorder,

          7. Presence of any bleeding disorders or conditions that prolongs bleeding time,

          8. History of allergy to vaccine components,

          9. Receipt of any other investigational product within 30 days prior to entry into the
             study,

         10. History of previous H5N1 vaccination,

         11. Receipt of any other type of seasonal vaccination within 2 months prior to entry into
             the study,

         12. Receipt of any other vaccine within 2 weeks prior to entry into the study

         13. Body temperature ≥38°C.0 (≥100.4° F) and/or acute illness within 3 days of intended
             study vaccination,

         14. Pregnant or breast feeding,

         15. Females of childbearing potential refusing to use acceptable method of birth control,

         16. Body mass index (BMI) ≥ 35 kg/m2,

         17. History of drug or alcohol abuse,

         18. Any planned surgery during study period,

         19. Individuals conducting the study and their immediate family members,

         20. Individuals with behavioral or cognitive impairment or psychiatric diseases.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Vaccines and Diagnostics</last_name>
    <role>Study Chair</role>
    <affiliation>Novartis Vaccines</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1 Miami Research Associates</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>2 Mercy Health Research</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>3 Saint Louis University</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>4 Benchmark Medical Research</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>48 Hunter Clinical Research</name>
      <address>
        <city>Newcastle</city>
        <state>New South Wales</state>
        <zip>2292</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>46 CMAX</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>47 Linear Clinical Research</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>80 Faculty of Tropical Medicine</name>
      <address>
        <city>Bangkok</city>
        <zip>1040</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Thailand</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 20, 2013</study_first_submitted>
  <study_first_submitted_qc>January 23, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2013</study_first_posted>
  <results_first_submitted>January 20, 2015</results_first_submitted>
  <results_first_submitted_qc>January 20, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 3, 2015</results_first_posted>
  <last_update_submitted>January 20, 2015</last_update_submitted>
  <last_update_submitted_qc>January 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza, Pandemic, H5N1, Adults</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
    <mesh_term>Influenza in Birds</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were enrolled at 4 centers in the US, 3 centers in Australia and 1 center in Thailand.</recruitment_details>
      <pre_assignment_details>All enrolled subjects were included in the trial.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>High Dose</title>
          <description>Subjects received 2 injections of a high dose of cell culture-derived adjuvanted monovalent inactivated subunit H5N1 vaccine three weeks apart.</description>
        </group>
        <group group_id="P2">
          <title>Low Dose</title>
          <description>Subjects received 2 injections of a low dose of cell culture-derived adjuvanted monovalent inactivated subunit H5N1 vaccine three weeks apart.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="488"/>
                <participants group_id="P2" count="491"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="432"/>
                <participants group_id="P2" count="416"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="56"/>
                <participants group_id="P2" count="75"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Administrative Reason</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="48"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unclassified</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>High Dose</title>
          <description>Subjects received 2 injections of a high dose MF59 adjuvanted cell-culture derived monovalent H5N1 vaccine three weeks apart.</description>
        </group>
        <group group_id="B2">
          <title>Low Dose</title>
          <description>Subjects received 2 injections of a low dose MF59 adjuvanted cell-culture derived monovalent H5N1 vaccine three weeks apart.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="488"/>
            <count group_id="B2" value="491"/>
            <count group_id="B3" value="979"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.0" spread="13.7"/>
                    <measurement group_id="B2" value="38.4" spread="14.2"/>
                    <measurement group_id="B3" value="38.7" spread="14.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="285"/>
                    <measurement group_id="B2" value="259"/>
                    <measurement group_id="B3" value="544"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="203"/>
                    <measurement group_id="B2" value="232"/>
                    <measurement group_id="B3" value="435"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentages Of Subjects Achieving Hemagglutinin Inhibition (HI) Titers ≥40 Against A/H5N1 Strain.</title>
        <description>The optimal aH5N1c vaccine formulation was evaluated in terms of percentages of subjects achieving HI titers ≥40 against homologous A/H5N1 strain, three weeks after second vaccination with either low dose or high dose of aH5N1c vaccine, according to the Center for Biologics Evaluation and Research (CBER) criterion.
CBER criterion for the adult population is met if the lower limit of the two-sided 95% confidence interval (CI) for the percentages of subjects achieving HI titer ≥40 meets or exceeds 70%.</description>
        <time_frame>Three weeks after 2nd vaccination (day 43)</time_frame>
        <population>Analysis was done on the Full Analysis Set (FAS) i.e., the subjects who actually receive at least one dose of study vaccination and provide at least one evaluable serum sample both before (baseline) and after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>High Dose</title>
            <description>Subjects received 2 injections of a high dose MF59 adjuvanted cell-culture derived monovalent H5N1 vaccine three weeks apart.</description>
          </group>
          <group group_id="O2">
            <title>Low Dose</title>
            <description>Subjects received 2 injections of a low dose MF59 adjuvanted cell-culture derived monovalent H5N1 vaccine three weeks apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages Of Subjects Achieving Hemagglutinin Inhibition (HI) Titers ≥40 Against A/H5N1 Strain.</title>
          <description>The optimal aH5N1c vaccine formulation was evaluated in terms of percentages of subjects achieving HI titers ≥40 against homologous A/H5N1 strain, three weeks after second vaccination with either low dose or high dose of aH5N1c vaccine, according to the Center for Biologics Evaluation and Research (CBER) criterion.
CBER criterion for the adult population is met if the lower limit of the two-sided 95% confidence interval (CI) for the percentages of subjects achieving HI titer ≥40 meets or exceeds 70%.</description>
          <population>Analysis was done on the Full Analysis Set (FAS) i.e., the subjects who actually receive at least one dose of study vaccination and provide at least one evaluable serum sample both before (baseline) and after vaccination.</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="478"/>
                <count group_id="O2" value="483"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="3" upper_limit="6"/>
                    <measurement group_id="O2" value="4" lower_limit="2" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43 (N=451,440)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85" lower_limit="81" upper_limit="88"/>
                    <measurement group_id="O2" value="63" lower_limit="58" upper_limit="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentages Of Subjects Achieving Seroconversion Against A/H5N1 Strain.</title>
        <description>Immunogenicity was measured in terms of the percentages of subjects achieving seroconversion or significant increase in HI titer against the vaccine strain, three weeks after receiving two injections of low dose or high dose of aH5N1c vaccine according to the CBER criterion.
Seroconversion is defined as either a) in subjects with a prevaccination HI titer &lt;10, a postvaccination titer ≥40; or b) in subjects with prevaccination HI titer ≥10, a minimum four-fold rise in postvaccination HI antibody titer.
CBER criterion for the adult population is met if the lower limit of the two-sided 95% CI for the percentages of subjects achieving seroconversion for HI antibody titer meets or exceeds 40%.</description>
        <time_frame>Three weeks after 2nd vaccination (day 43)</time_frame>
        <population>This analysis was done on the FAS population.</population>
        <group_list>
          <group group_id="O1">
            <title>High Dose</title>
            <description>Subjects received 2 injections of a high dose MF59 adjuvanted cell-culture derived monovalent H5N1 vaccine three weeks apart.</description>
          </group>
          <group group_id="O2">
            <title>Low Dose</title>
            <description>Subjects received 2 injections of a low dose MF59 adjuvanted cell-culture derived monovalent H5N1 vaccine three weeks apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages Of Subjects Achieving Seroconversion Against A/H5N1 Strain.</title>
          <description>Immunogenicity was measured in terms of the percentages of subjects achieving seroconversion or significant increase in HI titer against the vaccine strain, three weeks after receiving two injections of low dose or high dose of aH5N1c vaccine according to the CBER criterion.
Seroconversion is defined as either a) in subjects with a prevaccination HI titer &lt;10, a postvaccination titer ≥40; or b) in subjects with prevaccination HI titer ≥10, a minimum four-fold rise in postvaccination HI antibody titer.
CBER criterion for the adult population is met if the lower limit of the two-sided 95% CI for the percentages of subjects achieving seroconversion for HI antibody titer meets or exceeds 40%.</description>
          <population>This analysis was done on the FAS population.</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="451"/>
                <count group_id="O2" value="440"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83" lower_limit="79" upper_limit="86"/>
                    <measurement group_id="O2" value="61" lower_limit="56" upper_limit="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AE), After Any Vaccination.</title>
        <description>Safety was assessed using the number of subjects who reported solicited local and systemic AEs following vaccination with either low or high dose of aH5N1c vaccine.</description>
        <time_frame>From day 1 through day 7 after any vaccination.</time_frame>
        <population>Analysis was done on the safety dataset, i.e. the subjects in the exposed population who provided postvaccination safety data.</population>
        <group_list>
          <group group_id="O1">
            <title>High Dose</title>
            <description>Subjects received 2 injections of a high dose MF59 adjuvanted cell-culture derived monovalent H5N1 vaccine three weeks apart.</description>
          </group>
          <group group_id="O2">
            <title>Low Dose</title>
            <description>Subjects received 2 injections of a low dose MF59 adjuvanted cell-culture derived monovalent H5N1 vaccine three weeks apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AE), After Any Vaccination.</title>
          <description>Safety was assessed using the number of subjects who reported solicited local and systemic AEs following vaccination with either low or high dose of aH5N1c vaccine.</description>
          <population>Analysis was done on the safety dataset, i.e. the subjects in the exposed population who provided postvaccination safety data.</population>
          <units>Number of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="473"/>
                <count group_id="O2" value="471"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Local</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="322"/>
                    <measurement group_id="O2" value="236"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site Erythema(N=471,471)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site Induration(N=471,471)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site Ecchymosis(N=472,471)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site Pain(N=471,470)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="318"/>
                    <measurement group_id="O2" value="235"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Systemic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="223"/>
                    <measurement group_id="O2" value="209"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea(N=472,471)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia(N=472,469)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108"/>
                    <measurement group_id="O2" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arthralgia(N=471,467)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                    <measurement group_id="O2" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache(N=471,469)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="126"/>
                    <measurement group_id="O2" value="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue(N=471,469)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="125"/>
                    <measurement group_id="O2" value="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Loss of Appetite(N=472,469)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise(N=472,467)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117"/>
                    <measurement group_id="O2" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (≥38°C)(N=472,469)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment of pain and (or) fever(N=471,470)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prevention of pain and (or) fever(N=471,470)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (≥40°C)(N=472,469)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Reporting Unsolicited AEs After Any Vaccination.</title>
        <description>Safety was assessed using the number of subjects who reported any unsolicited adverse events, adverse events possibly or probably related to study vaccine, serious adverse events (SAEs), new onset of chronic diseases (NOCDs), medically attended AEs, AEs of special interest (AESIs), AEs leading to withdrawal from study following vaccination with either low or high dose of aH5N1c vaccine.</description>
        <time_frame>Any unsolicited AEs - day 1 through day 22 after any vaccination. SAEs, NOCDs. medically attended AEs, AESIs, AEs leading to study withdrawal- day 1 to day 387</time_frame>
        <population>Analysis was done on the safety dataset, i.e. the subjects in the exposed population who provided postvaccination safety data.</population>
        <group_list>
          <group group_id="O1">
            <title>High Dose</title>
            <description>Subjects received 2 injections of a high dose MF59 adjuvanted cell-culture derived monovalent H5N1 vaccine three weeks apart.</description>
          </group>
          <group group_id="O2">
            <title>Low Dose</title>
            <description>Subjects received 2 injections of a low dose MF59 adjuvanted cell-culture derived monovalent H5N1 vaccine three weeks apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Unsolicited AEs After Any Vaccination.</title>
          <description>Safety was assessed using the number of subjects who reported any unsolicited adverse events, adverse events possibly or probably related to study vaccine, serious adverse events (SAEs), new onset of chronic diseases (NOCDs), medically attended AEs, AEs of special interest (AESIs), AEs leading to withdrawal from study following vaccination with either low or high dose of aH5N1c vaccine.</description>
          <population>Analysis was done on the safety dataset, i.e. the subjects in the exposed population who provided postvaccination safety data.</population>
          <units>Number of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="476"/>
                <count group_id="O2" value="475"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94"/>
                    <measurement group_id="O2" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At least possibly related AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medically attended AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="171"/>
                    <measurement group_id="O2" value="153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs resulting in premature withdrawal from study</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs of Special Interest</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs leading to New Onset of Chronic Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Ratios Against A/H5N1 Strain Following 2-dose Vaccination Schedule of Either Low Dose or High Dose aH5N1c Vaccine.</title>
        <description>Immunogenicity was measured as the geometric mean ratio (GMR). The ratio of postvaccination to prevaccination HI GMTs, 3 weeks after first vaccination, 3 weeks after second vaccination and 12 months after second vaccination of either low dose or high dose of aH5N1c is reported.
The criterion is met according to the European Committee for Medicinal Products for Human Use (CHMP) criterion if the geometric mean increase GMR (day 43/day 1) in HI antibody titer is &gt;2.5 for subjects 18-60 years of age.</description>
        <time_frame>Day 1; day 22; day 43 and day 387</time_frame>
        <population>Analysis was done on the FAS set.</population>
        <group_list>
          <group group_id="O1">
            <title>High Dose</title>
            <description>Subjects received 2 injections of a high dose MF59 adjuvanted cell-culture derived monovalent H5N1 vaccine three weeks apart.</description>
          </group>
          <group group_id="O2">
            <title>Low Dose</title>
            <description>Subjects received 2 injections of a low dose MF59 adjuvanted cell-culture derived monovalent H5N1 vaccine three weeks apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Ratios Against A/H5N1 Strain Following 2-dose Vaccination Schedule of Either Low Dose or High Dose aH5N1c Vaccine.</title>
          <description>Immunogenicity was measured as the geometric mean ratio (GMR). The ratio of postvaccination to prevaccination HI GMTs, 3 weeks after first vaccination, 3 weeks after second vaccination and 12 months after second vaccination of either low dose or high dose of aH5N1c is reported.
The criterion is met according to the European Committee for Medicinal Products for Human Use (CHMP) criterion if the geometric mean increase GMR (day 43/day 1) in HI antibody titer is &gt;2.5 for subjects 18-60 years of age.</description>
          <population>Analysis was done on the FAS set.</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="464"/>
                <count group_id="O2" value="461"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day22/Day1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.37" lower_limit="4.6" upper_limit="6.27"/>
                    <measurement group_id="O2" value="2.43" lower_limit="2.07" upper_limit="2.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day43/Day1 (N=451,440)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41" lower_limit="34" upper_limit="49"/>
                    <measurement group_id="O2" value="11" lower_limit="8.68" upper_limit="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day387/Day1 (N=411,395)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.95" lower_limit="1.73" upper_limit="2.19"/>
                    <measurement group_id="O2" value="1.24" lower_limit="1.1" upper_limit="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages Of Subjects With HI Titers ≥40 Against A/H5N1 Strain.</title>
        <description>Immunogenicity was assessed in terms of percentage of subjects achieving HI titers ≥40, 3 weeks after first vaccination, 3 weeks after second vaccination and 12 months after second vaccination of either low dose or high dose of aH5N1c according to the CHMP criterion.
European Licensure (CHMP) criterion is met if the percentage of subjects achieving (at day 43) HI titers ≥40 is &gt;70%.</description>
        <time_frame>Day 1, day 22, day 43 and day 387</time_frame>
        <population>Analysis was done on the FAS set.</population>
        <group_list>
          <group group_id="O1">
            <title>High Dose</title>
            <description>Subjects received 2 injections of a high dose MF59 adjuvanted cell-culture derived monovalent H5N1 vaccine three weeks apart.</description>
          </group>
          <group group_id="O2">
            <title>Low Dose</title>
            <description>Subjects received 2 injections of a low dose MF59 adjuvanted cell-culture derived monovalent H5N1 vaccine three weeks apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages Of Subjects With HI Titers ≥40 Against A/H5N1 Strain.</title>
          <description>Immunogenicity was assessed in terms of percentage of subjects achieving HI titers ≥40, 3 weeks after first vaccination, 3 weeks after second vaccination and 12 months after second vaccination of either low dose or high dose of aH5N1c according to the CHMP criterion.
European Licensure (CHMP) criterion is met if the percentage of subjects achieving (at day 43) HI titers ≥40 is &gt;70%.</description>
          <population>Analysis was done on the FAS set.</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="478"/>
                <count group_id="O2" value="483"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="3" upper_limit="6"/>
                    <measurement group_id="O2" value="4" lower_limit="2" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22 (N=464,461)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52" lower_limit="47" upper_limit="56"/>
                    <measurement group_id="O2" value="30" lower_limit="26" upper_limit="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43 (N=451,440)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85" lower_limit="81" upper_limit="88"/>
                    <measurement group_id="O2" value="63" lower_limit="58" upper_limit="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 387 (N=411,395)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27" lower_limit="22" upper_limit="31"/>
                    <measurement group_id="O2" value="11" lower_limit="8" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages Of Subjects Achieving Seroconversion Against A/H5N1 Strain.</title>
        <description>Immunogenicity was assessed in terms of percentages of subjects achieving seroconversion in HI titers, 3 weeks after first vaccination, 3 weeks after second vaccination and 12 months after second vaccination of either low dose or high dose aH5N1c vaccine according to the CHMP criterion.
Seroconversion is defined as: a) for subjects with a prevaccination HI titer &lt;10, a postvaccination titer ≥40; or b) for subjects with prevaccination HI titer ≥10, a minimum four-fold rise in postvaccination HI antibody titer.
The criterion is met according to the European (CHMP) guideline if the percentage of subjects achieving seroconversion (at day 43) is &gt;40%.</description>
        <time_frame>Day 22, day 43 and day 387</time_frame>
        <population>Analysis was done on the FAS set.</population>
        <group_list>
          <group group_id="O1">
            <title>High Dose</title>
            <description>Subjects received 2 injections of a high dose MF59 adjuvanted cell-culture derived monovalent H5N1 vaccine three weeks apart.</description>
          </group>
          <group group_id="O2">
            <title>Low Dose</title>
            <description>Subjects received 2 injections of a low dose MF59 adjuvanted cell-culture derived monovalent H5N1 vaccine three weeks apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages Of Subjects Achieving Seroconversion Against A/H5N1 Strain.</title>
          <description>Immunogenicity was assessed in terms of percentages of subjects achieving seroconversion in HI titers, 3 weeks after first vaccination, 3 weeks after second vaccination and 12 months after second vaccination of either low dose or high dose aH5N1c vaccine according to the CHMP criterion.
Seroconversion is defined as: a) for subjects with a prevaccination HI titer &lt;10, a postvaccination titer ≥40; or b) for subjects with prevaccination HI titer ≥10, a minimum four-fold rise in postvaccination HI antibody titer.
The criterion is met according to the European (CHMP) guideline if the percentage of subjects achieving seroconversion (at day 43) is &gt;40%.</description>
          <population>Analysis was done on the FAS set.</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="464"/>
                <count group_id="O2" value="461"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48" lower_limit="44" upper_limit="53"/>
                    <measurement group_id="O2" value="27" lower_limit="23" upper_limit="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43 (N=451,440)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83" lower_limit="71" upper_limit="91"/>
                    <measurement group_id="O2" value="61" lower_limit="45" upper_limit="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 387 (N=411,395)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22" lower_limit="18" upper_limit="26"/>
                    <measurement group_id="O2" value="9" lower_limit="6" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Solicited local and systemic adverse events from day 1 to 7. SAEs and Unsolicited AEs (other than SAEs) from day 1 to 387.</time_frame>
      <desc>All Solicited AEs are classified as systematic assessment and all unsolicited AEs are classified as non-systematic assessment.
Subjects who did not provide unsolicited safety data were excluded from safety evaluation.</desc>
      <group_list>
        <group group_id="E1">
          <title>High Dose</title>
          <description>Subjects received 2 injections of a high dose of cell culture-derived adjuvanted monovalent inactivated subunit H5N1 vaccine three weeks apart.</description>
        </group>
        <group group_id="E2">
          <title>Low Dose</title>
          <description>Subjects received 2 injections of a low dose of cell culture-derived adjuvanted monovalent inactivated subunit H5N1 vaccine three weeks apart.</description>
        </group>
        <group group_id="E3">
          <title>Total</title>
          <description>Total of high dose and low dose groups.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="485"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="490"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="975"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="490"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="975"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>PANCREATITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="490"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="975"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>NON-CARDIAC CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="490"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="975"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>CHOLECYSTITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="490"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="975"/>
              </event>
              <event>
                <sub_title>CHOLELITHIASIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="490"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="975"/>
              </event>
              <event>
                <sub_title>JAUNDICE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="490"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="975"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>APPENDICITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="490"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="975"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS VIRAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="490"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="975"/>
              </event>
              <event>
                <sub_title>INFLUENZA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="490"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="975"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="485"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="490"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="975"/>
              </event>
              <event>
                <sub_title>PYELONEPHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="490"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="975"/>
              </event>
              <event>
                <sub_title>SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="485"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="490"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="975"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>BRAIN CONTUSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="490"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="975"/>
              </event>
              <event>
                <sub_title>CONTUSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="490"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="975"/>
              </event>
              <event>
                <sub_title>LIMB CRUSHING INJURY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="490"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="975"/>
              </event>
              <event>
                <sub_title>POST LAMINECTOMY SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="490"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="975"/>
              </event>
              <event>
                <sub_title>POSTOPERATIVE ADHESION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="490"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="975"/>
              </event>
              <event>
                <sub_title>ROAD TRAFFIC ACCIDENT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="490"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="975"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>LARYNGEAL SQUAMOUS CELL CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="490"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="975"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CEREBRAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="490"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="975"/>
              </event>
              <event>
                <sub_title>NERVE COMPRESSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="490"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="975"/>
              </event>
              <event>
                <sub_title>SUBARACHNOID HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="490"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="975"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>ABORTION MISSED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="490"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="975"/>
              </event>
              <event>
                <sub_title>ABORTION SPONTANEOUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="490"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="975"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>NEPHROLITHIASIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="485"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="490"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="975"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="490"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="975"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>RAYNAUD'S PHENOMENON</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="490"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="975"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="371" subjects_at_risk="485"/>
                <counts group_id="E2" subjects_affected="324" subjects_at_risk="490"/>
                <counts group_id="E3" subjects_affected="695" subjects_at_risk="975"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="485"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="490"/>
                <counts group_id="E3" subjects_affected="109" subjects_at_risk="975"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" subjects_affected="125" subjects_at_risk="485"/>
                <counts group_id="E2" subjects_affected="111" subjects_at_risk="490"/>
                <counts group_id="E3" subjects_affected="236" subjects_at_risk="975"/>
              </event>
              <event>
                <sub_title>INJECTION SITE ERYTHEMA</sub_title>
                <counts group_id="E1" subjects_affected="76" subjects_at_risk="485"/>
                <counts group_id="E2" subjects_affected="61" subjects_at_risk="490"/>
                <counts group_id="E3" subjects_affected="137" subjects_at_risk="975"/>
              </event>
              <event>
                <sub_title>INJECTION SITE HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="485"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="490"/>
                <counts group_id="E3" subjects_affected="70" subjects_at_risk="975"/>
              </event>
              <event>
                <sub_title>INJECTION SITE INDURATION</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="485"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="490"/>
                <counts group_id="E3" subjects_affected="100" subjects_at_risk="975"/>
              </event>
              <event>
                <sub_title>INJECTION SITE PAIN</sub_title>
                <counts group_id="E1" subjects_affected="319" subjects_at_risk="485"/>
                <counts group_id="E2" subjects_affected="244" subjects_at_risk="490"/>
                <counts group_id="E3" subjects_affected="563" subjects_at_risk="975"/>
              </event>
              <event>
                <sub_title>MALAISE</sub_title>
                <counts group_id="E1" subjects_affected="117" subjects_at_risk="485"/>
                <counts group_id="E2" subjects_affected="97" subjects_at_risk="490"/>
                <counts group_id="E3" subjects_affected="214" subjects_at_risk="975"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="485"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="490"/>
                <counts group_id="E3" subjects_affected="97" subjects_at_risk="975"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DECREASED APPETITE</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="485"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="490"/>
                <counts group_id="E3" subjects_affected="94" subjects_at_risk="975"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" subjects_affected="75" subjects_at_risk="485"/>
                <counts group_id="E2" subjects_affected="60" subjects_at_risk="490"/>
                <counts group_id="E3" subjects_affected="135" subjects_at_risk="975"/>
              </event>
              <event>
                <sub_title>MYALGIA</sub_title>
                <counts group_id="E1" subjects_affected="112" subjects_at_risk="485"/>
                <counts group_id="E2" subjects_affected="82" subjects_at_risk="490"/>
                <counts group_id="E3" subjects_affected="194" subjects_at_risk="975"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="134" subjects_at_risk="485"/>
                <counts group_id="E2" subjects_affected="120" subjects_at_risk="490"/>
                <counts group_id="E3" subjects_affected="255" subjects_at_risk="975"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Posting Director</name_or_title>
      <organization>Novartis Vaccines and Diagnostics</organization>
      <email>RegistryContactVaccinesUS@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

